Incorporation of excess gadolinium into human bone from medical contrast agents

Metallomics

Volumn 1, Issue 6, 2009, Pages 479-488

  Darrah, Thomas H ^a,d   Prutsman Pfeiffer, Jennifer J ^b   Poreda, Robert J ^a   Ellen Campbell, M ^a,d   Hauschka, Peter V ^c   Hannigan, Robyn E ^d  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACKGROUND LEVEL; BONE RESORPTION; BONE TISSUE; BREAK DOWN; CELLULAR PROCESS; CONTRAST AGENT; CONTROL GROUPS; DIFFERENT MECHANISMS; FEMORAL HEADS; HIGH CONCENTRATION; HUMAN BONES; IN-VIVO; MEDICAL CONDITIONS; METAL INCORPORATION; NEPHROGENIC SYSTEMIC FIBROSIS; OSTEOPOROTIC; OSTEOPOROTIC FRACTURES;

BONE; CHELATION; MEDICAL IMAGING; TISSUE;

GADOLINIUM;

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM; GADOTERIDOL;

ARTICLE; BONE TISSUE; CALCULATION; CONTROLLED STUDY; DISSOLUTION; FEMUR HEAD; FRACTURE; HUMAN; HUMAN TISSUE; MENOPAUSE; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PREGNANT WOMAN; PRIORITY JOURNAL;

BONE AND BONES; CASE-CONTROL STUDIES; CONTRAST MEDIA; DIAGNOSTIC IMAGING; FEMUR HEAD; FRACTURES, BONE; GADOLINIUM; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOARTHRITIS; TISSUE DISTRIBUTION;

EID: 77954679114     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/b905145g     Document Type: Article

References (67)

1. C. Thakral J. Alhariri J. L. Abraham Long-term Retention of Gadolinium in Tissues from Nephrogenic System Fibrosis Patient after Multiple Gadolinium-enhanced MRI Scans: A Case Report and Implications Contrast Media Mol. Imaging 2007 2 199 205 (Pubitemid 47542596)
2. J. M. Idee, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review Fundam. Clin. Pharmacol. 2006 20 563 576
3. V. M. Runge J. R. Parker Worldwide clinical safety assessment of gadoteridol injection: an update Eur. Radiol. 1997 7 S243 S245
4. H. Sato S. Takahashi Y. Kubota Effects of gadolinium on the retention and translocation of Pu-239-hydroxide Health Phys. 2001 80 164 169 (Pubitemid 32107297)
5. H. J. Weinmann R. C. Brasch W. R. Press G. E. Wesbey Characteristics of gadolinium-DTPA complex-a potential NMR contrast agent Am. J. Roentgenol. 1984 142 619 624
6. V. M. Runge, et al. MR imaging section profile optimization - improved contrast and detection of lesions Radiology 1988 167 831 834
7. V. M. Runge GD-DPTA-AN IV contrast agent for clinical MRI Nucl. Med. Biol. 1988 15 37 44
8. D. R. Broome, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned American Journal of Roentgenology 2007 188 586 592
9. B. A. Biagi J. J. Enyeart Gadolinium blocks low-threshold and high-threshold calcium currents in pituitary-cells Am. J. Physiol.: Cell Physiol. 1990 259 C515 C520
10. F. G. Shellock A. Spinazzi MRI Safety Update 2008: Part I, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol. 2008 191 1129 1139
11. R. A. Caldwell H. F. Clemo C. M. Baumgarten Using gadolinium to identify stretch-activated channels: technical considerations Am. J. Physiol.: Cell Physiol. 1998 275 C619 C621
12. X. C. Yang F. Sachs Block of stretch-activated ion channels in xenopus oocytes by gadolinium and calcium-ions Science 1989 243 1068 1071 (Pubitemid 19072584)
13. J. E. Molgo J. Delpozo E. Banos D. Angautpetit Changes of quantal transmitter release caused by gadolinium ions at the frog neuromuscular-junction Br. J. Pharmacol. 1991 104 133 138
14. M. F. Tweedle The ProHance story: the making of a novel MRI contrast agent Eur. Radiol. 1997 7 S225 S230
15. J. L. Abraham C. Thakral Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis Eur. J. Radiol. 2008 66 200 207
16. J. S. Mann Stability of gadolinium complexes invitro and invivo J. Comput. Assist. Tomo. 1993 17 S19 S23
17. J. P. Weigle D. R. Broome Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature Skeletal Radiol. 2008 37 457 464
18. S. Laurent L. V. Elst R. N. Muller Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents Contrast Media Mol. Imaging 2006 1 128 137
19. 3+ ions Contrast Media Mol. Imaging 2006 1 23 29
20. G. R. Moran R. E. Thornhill J. Sykes F. S. Prato Myocardial viability imaging using Gd-DTPA: Physiological modeling of infarcted myocardium and impact on injection strategy and imaging time Magn. Reson. Med. 2002 48 791 800 (Pubitemid 35340319)
21. O. J. Badero L. Schlanger D. Rizk Gadolinium nephrotoxicity: case report of a rare entity and review of the literature Clin. Nephrol. 2008 70 518 522
22. M. E. Bartolini, et al. An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis Magn. Reson. Imaging 2003 21 541 544
23. T. Grobner Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol., Dial., Transplant. 2006 21 1104 1108
24. P. Marckmann L. Skov K. Rossen J. G. Heaf H. S. Thomsen Case-control study of gadodiamide-related nephrogenic systemic fibrosis Nephrol., Dial., Transplant. 2007 22 3174 3178 (Pubitemid 350202540)
25. J. M. Idee C. Corot Anaphylactic shock after first exposure to a macrocyclic gadolinium chelate: A few comments J. Allergy Clin. Immunol. 2008 122 215 216
26. I. Ergun, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure Nephrol., Dial., Transplant. 2006 21 697 700 (Pubitemid 43372917)
27. J. Kay Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction Ann. Rheum. Dis. 2008 67 iii66 iii69
28. R. E. Kalb, et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury Br. J. Dermatol. 2008 158 607 610
29. P. Marckmann, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J. Am. Soc. Nephrol. 2006 17 2359 2362
30. C. Thakral J. L. Abraham Automated scanning electron microscopy and X-ray microanalysis for in situ quantification of Gadolinium deposits in skin J. Electron Microsc. 2007 56 181 187
31. W. A. Gibby K. A. Gibby W. A. Gibby Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy Invest. Radiol. 2004 39 138 142
32. H. C. Skinner W. Biominerals Mineral. Mag. 2005 69 621 641
33. J. D. Pasteris B. Wopenka E. Valsami-Jones Bone and tooth mineralization: Why apatite? Elements 2008 4 97 104
34. M. Berglund A. Akesson P. Bjellerup M. Vahter Metal-Bone Interact. 2000 219 225
35. S. G. Dahl, et al. Incorporation and distribution of strontium in bone Bone 2001 28 446 453
36. A. L. Boskey Biomineralization: An overview Connect. Tissue Res. 2003 44 Suppl. 1 5 9
37. A. L. Boskey Mineral analysis provides insights into the mechanism of biomineralization Calcif. Tissue Int. 2003 72 533 536 (Pubitemid 36958553)
38. B. Gulson, et al. Skeletal lead release during bone resorption: Effect of bisphosphonate treatment in a pilot study Environ. Health Perspect. 2002 110 1017 1023
39. Z. P. Li K. M. Kong W. L. Qi Osteoclast and its roles in calcium metabolism and bone development and remodeling Biochem. Biophys. Res. Commun. 2006 343 345 350
40. E. F. Eriksen, et al. Cancellous bone remodeling in type-I (postmenopausal) osteoporosis-quantitative assessment of rates of formation, resorption and bone loss at tissue and cellular-levels J. Bone Miner. Res. 1990 5 311 319
41. B. L. Gulson, et al. Contribution of tissue lead to blood lead in adult female subjects based on stable lead-isotope methods J. Lab. Clin. Med. 1995 125 703 712
42. S. J. Rothenberg, et al. Changes in serial blood lead levels during pregnancy Environ. Health Perspect. 1994 102 876 880 (Pubitemid 24350639)
43. B. L. Gulson, et al. Pregnancy increases mobilization of lead from maternal skeleton J. Lab. Clin. Med. 1997 130 51 62
44. V. Chavagnac, et al. Towards the development of a fossil bone geochemical standard: An inter-laboratory study Anal. Chim. Acta 2007 599 177 190
45. NIST. Bone Meal Standard Reference Material Certificate 1486. in Standard Reference Materials (ed. N.I. Technology, o.S.a.) (2007)
46. USEPA. US EPA SW-846 Method 6020A. Analysis of soils and sediments by inductively coupled plasma- mass spectrometry. (ed. U.S. Agency, E.P.) (1991)
47. USEPA. EPA 200.8 Determination of trace elements in waters and waste waters by inductively copuled plasma- mass spectrometry. (ed. U.S. Environmental Protection Agency, O.o.R.a.D.) (1994)
48. G. J. Long J. D. Winefordner Limit of detection, a closer look at the IUPAC definition Anal. Chem. 1983 55 712A 724A
49. USEPA. Title 40 of the US Code of Federal Regulations, Part 136, Appendix B. (ed. Administration, O.o.t.F.R.N.A.a.R.) (Washington, DC, 1993)
50. M. Bau P. Dulski Anthropogenic origin of positive gadolinium anomalies in river waters Earth Planet. Sci. Lett. 1996 143 245 255 (Pubitemid 27138975)
51. S. M. Rocklage The relationship between thermodynamics and the toxicity of gadolinium complexes Abstr. Pap. Am. Chem. Soc. 1991 201 457
52. S. K. Morcos Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol. 2007 80 73 76
53. Rare earth element concentrations, speciation, and fractionation along groundwater flow paths; the Carrizo Sand (Texas) and Upper Floridan aquifers, ed., J. Tang, and, K. H. Johannesson,, Springer, Dordrecht, Netherlands, 2005, pp. 223-251
54. C. N. Trueman A. K. Behrensmeyer R. Potts N. Tuross High-resolution records of location and stratigraphic provenance from the rare earth element composition of fossil bones Geochim. Cosmochim. Acta 2006 70 4343 4355 (Pubitemid 44294043)
55. B. Hamm, et al. Phase-I clinical-evaluation of GD-EOB-DTPA as a hepatobiliary Mr contrast agent-safety, Pharmacokinetics and MR-imaging Radiology 1995 195 785 792
56. V. M. Runge, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology Invest. Radiol. 2001 36 65 71
57. O. Dohr R. Hofmeister M. Treher H. Schweinfurth Preclinical safety evaluation of Gd-EOB-DTPA (Primovist) Invest. Radiol. 2007 42 830 841 (Pubitemid 350126565)
58. J. L. Abraham C. Thakral L. Skov K. Rossen P. Marckmann Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis Br. J. Dermatol. 2008 158 273 280
59. D. R. Broome Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting Eur. J. Radiol. 2008 66 230 234
60. M. Trotter B. B. Hixon Changes in weight, density and percentage ash weight of skeleton from early fetal life through old AGE Am. J. Phys. Anthropol. 1974 41 507 507
61. M. J. Glimcher Bone: Nature of the calcium phosphate crystals and cellular, structural and physical chemical mechanisms in their formation Rev. Mineral. Geochem. 2006 64 223 282
62. USGS. Rare Earth Elements-Critical Resources for High Technology. in Fact Sheet (ed. USGS) 1-4 (2002).
63. M. F. Tweedle Physicochemical properties of gadoteridol and other magnetic-resonance contrast agents Invest. Radiol. 1992 27 S7 S6
64. J. J. Carmouche, et al. Lead exposure inhibits fracture healing and is associated with increased chondrogenesis, delay in cartilage mineralization and a decrease in osteoprogenitor frequency Environ. Health Perspect. 2005 113 749 755
65. J. E. Puzas M. J. Sickel M. E. Felter Osteoblasts and chondrocytes are important target-cells for the toxic effects of lead Neurotoxicology 1992 13 783 788
66. T. L. Dowd J. F. Rosen L. Mints C. M. Gundberg The effect of Pb2+ on the structure and hydroxyapatite binding properties of osteocalcin Biochim. Biophys. Acta, Mol. Basis Dis. 2001 1535 153 163 (Pubitemid 32112761)
67. K. R. Mahaffey J. L. Annest J. Roberts R. S. Murphy National estimates of blood lead levels-united-states 1976-1980-Association with selected demographic and socio-economic factors New Engl. J. Med. 1982 307 573 579 (Pubitemid 12043958)